• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Fzata, Inc.

Wednesday, June 05, 2024
Start-Up Stadium Session
Platform for Therapeutics
Company Description: Fzata (fzata.com) has solved the oral biologics problem with the BIoPYM platform. Live yeast micro-factories make and secrete biologic therapeutic in the GI. Direct GI targeting avoids anti-drug antibody and systemic tox common to biologics like Humira which suffer upto a 50% discontinuation rate. We are an NIH Seed company with $17M non-dilutive. First in human clinical study will be 2024 for FZ002 c diff program fully supported by NIH. We are now raising seed $10M to support FZ006 IBD program. FZ006 will be the first oral anti-TNFalpha for IBD and also the first anti-TNFalpha for the mild-moderate IBD population. This is a multi-billion dollar market in the US alone and a huge unmet medical need.

Fzata, Inc.
Company Website: http://www.fzata.com

Company HQ City

Halethorpe

Company HQ State

Maryland

Company HQ Country

United States

CEO/Top Company Official

Zhiyong Yang, CEO
Primary Speaker
Elizabeth Smith, PhD
Chief Business Officer
Fzata, Inc.
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS